Antiplatelet therapy in ischemic stroke and transient ischemic attack: An overview of major trials and meta-analyses

Stroke

Volumn 50, Issue 3, 2019, Pages 773-778

  Hackam, Daniel G ^a   Spence, J David ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Aspirin; Clopidogrel; Platelet aggregation inhibitors; Risk; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT;

ANTIPLATELET ACTIVITY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DUAL ANTIPLATELET THERAPY; HUMAN; META ANALYSIS; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE PATIENT; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; COMBINATION DRUG THERAPY;

BRAIN ISCHEMIA; DRUG THERAPY, COMBINATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; STROKE;

EID: 85062178827     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.118.023954     Document Type: Review

References (37)

1. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, et al; Global Burden of Diseases, Injuries and Risk Factors Study 2013 and Stroke Experts Writing Group. Global burden of stroke and risk factors in 188 countries, during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016;15:913-924. doi: 10.1016/S1474-4422(16)30073-4
2. Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, et al; TIAregistry.org Investigators. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2016;374:1533-1542. doi: 10.1056/NEJMoa1412981
3. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024
4. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46-e110. doi: 10.1161/STR.0000000000000158
5. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-1218.
6. Korbut R, Moncada S. Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy. Thromb Res. 1978;13:489-500.
7. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
8. Chen ZM. CAST: Randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
9. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke. 2000;31:1240-1249.
10. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215-225. doi: 10.1056/NEJMoa1800410
11. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11-19. doi: 10.1056/NEJMoa1215340
12. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative metaanalysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860. doi: 10.1016/S0140-6736(09)60503-1
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
14. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;4:39-46.
15. Halkes PH, Gray LJ, Bath PM, Diener HC, Guiraud-Chaumeil B, Yatsu FM, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: A meta-analysis by risk. J Neurol Neurosurg Psychiatry. 2008;79:1218-1223. doi: 10.1136/jnnp.2008.143875
16. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A; ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet. 2006;367:1665-1673. doi: 10.1016/S0140-6736(06)68734-5
17. Second European Stroke Prevention Study. ESPS-2 Working Group. J Neurol. 1992;239:299-301.
18. de Vos-Koppelaar NC, Kerkhoff H, de Vogel EM, Zock E, Dieleman HG. The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: A randomized, open-label trial (DOSE). Cerebrovasc Dis. 2014;37:285-289. doi: 10.1159/000360751
19. Douen AG, Medic S, Sabih M, Pageau N, Shuaib A. Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse effects and improves tolerance in patients with stroke. J Stroke Cerebrovasc Dis. 2008;17:356-359. doi: 10.1016/j.jstrokecerebrovasdis.2008.04.003
20. Lipton RB, Bigal ME, Kolodner KB, Gorelick PB, Wilks K, Schoebelock M, et al. Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination. Neurology. 2004;63:1099-1101.
21. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251. doi: 10.1056/NEJMoa0805002
22. Gachet C, Stierlé A, Cazenave JP, Ohlmann P, Lanza F, Bouloux C, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol. 1990;40:229-238.
23. Meyer DM, Albright KC, Allison TA, Grotta JC. LOAD: A pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. J Stroke Cerebrovasc Dis. 2008;17:26-29. doi: 10.1016/j.jstrokecerebrovasdis.2007.09.006
24. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
25. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al; MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337. doi: 10.1016/S0140-6736(04)16721-4
26. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA; SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817-825. doi: 10.1056/NEJMoa1204133
27. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717. doi: 10.1056/NEJMoa060989
28. Hankey GJ, Hacke W, Easton JD, Johnston SC, Mas JL, Brennan DM, et al; CHARISMA Trial Investigators. Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: A prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke. 2010;41:1679-1683. doi: 10.1161/STROKEAHA.110.586727
29. Tantry US, Bliden KP, Gurbel PA. AZD6140. Expert Opin Investig Drugs. 2007;16:225-229. doi: 10.1517/13543784.16.2.225
30. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047. doi: 10.1093/eurheartj/ehi754
31. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35-43. doi: 10.1056/NEJMoa1603060
32. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al; SOCRATES Steering Committee and Investigators. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: A subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:301-310. doi: 10.1016/S1474-4422(17)30038-8
33. Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al; SOCRATES Steering Committee and Investigators. Efficacy and safety of ticagrelor in relation to aspirin use within the week before randomization in the SOCRATES trial. Stroke. 2018;49:1678-1685. doi: 10.1161/STROKEAHA.118.020553
34. Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study. Agespecific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: A population-based cohort study. Lancet. 2017;390:490-499. doi: 10.1016/S0140-6736(17)30770-5
35. Spence JD. Antihypertensive drugs and prevention of atherosclerotic stroke. Stroke. 1986;17:808-810.
36. North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke. 1991;22:711-720.
37. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1998;339:1415-1425. doi: 10.1056/NEJM199811123392002